2026, Clinical Pharmacology and Disease

Antibody Drug Conjugates: windows of opportunity

Drug Target Review

JULY 4, 2023

The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. In practice, some patients may be left managing a syndrome associated with the therapy along with the disease. Translational and Clinical Pharmacology [Internet]. 2022 [cited 2023 Feb 10];30(2):71.

Small Molecule

Small Molecule Drugs Clinical Pharmacology Trials

Analysis Life Sciences Thank You 166 guidance documents the FDA is actively working on in 2024 (and beyond)

Agency IQ

FEBRUARY 15, 2024

If you’re looking for something specific, we recommend using the search function in your browser (Ctrl-F) to look for keywords of interest.

FDA

FDA Science Biosimilars Clinical Trials

Analysis Life Sciences Thank You The 53 regulations that FDA is currently working on

Agency IQ

JULY 12, 2024

Specifically, FDA is proposing to classify blood irradiators intended for the prevention of transfusion-associated graft versus host disease into Class II and blood irradiators intended for prevention of metastasis by irradiating intra-operatively salvaged blood of cancer patients undergoing surgery into Class III.

Regulations

Regulations FDA Science Production

Drug Discovery Digest

Antibody Drug Conjugates: windows of opportunity

Analysis Life Sciences Thank You 166 guidance documents the FDA is actively working on in 2024 (and beyond)

Analysis Life Sciences Thank You The 53 regulations that FDA is currently working on

Stay Connected